1	Evaluation of the ID NOW Among Symptomatic
2	Individuals During the Omicron Wave
3 4 5	William Stokes ^{1,2,3} , MD, Allison A. Venner ^{1,4} , PhD, Emily Buss ¹ , Graham Tipples ^{1,2,5} , PhD, Byron M. Berenger ^{1,4} , MD
7 8 9 10 11 12 13	 ¹Alberta Precision Laboratories, Alberta, Canada ²Department of Pathology and Laboratory Medicine, University of Alberta, Alberta, Canada ³Division of Infectious Diseases, Department of Medicine, University of Alberta, Edmonton, Alberta ⁴Department of Pathology and Laboratory Medicine, University of Calgary, Calgary, Alberta, Canada ⁵Li Ka Shing Institute of Virology, University of Alberta, Edmonton, Alberta, Canada.
14 15	Corresponding author: William Stokes, William.Stokes@AlbertaPrecisionLabs.ca
16	
17	
18	
19	
20	
21	
22	
23	
24	
25	
26	
27	
28	
29	
30	

31 ABSTRACT

32 BACKGROUND

- 33 Point of Care SARS-CoV-2 devices, such as the Abbott ID NOW have great potential, to help
- 34 combat the COVID-19 pandemic. Starting in December, 2020, the ID NOW was implemented
- 35 throughout the province of Alberta, Canada (population 4.4 million) in various settings. We
- 36 aimed to assess the ID NOW performance during the BA.1 Omicron wave and compare it to
- 37 previous waves.

38 METHODS

- 39 The ID NOW was assessed in two distinct locations among symptomatic individuals: acute care
- 40 (emergency room, urgent care, and hospitalized patients) and community assessment centres
- 41 (AC) during the period January 5 18, 2022. Starting January 5, Omicron represented >95% of
- 42 variants detected in our population. For every individual tested, two swabs were collected: one
- 43 for ID NOW testing and the other for either reverse-transcriptase polymerase chain reaction (RT-
- 44 PCR) confirmation of negative ID NOW results or for variant testing of positive ID NOW
- 45 results.

46 **RESULTS**

- 47 A total of 3,041 paired samples were analyzed (1,139 RT-PCR positive). 1,873 samples were
- 48 from 42 COVID-19 AC and 1,168 from 69 rural hospitals. ID NOW sensitivity for symptomatic
- 49 individuals presenting to community AC and patients in hospital was 96.0% [95% confidence
- 50 interval (CI) 94.5-97.3%, n=830 RT-PCR positive], and 91.6% (95% CI 87.9-94.4%, n=309 RT-
- 51 PCR positive), respectively. SARS-CoV 2 positivity rate was very high for both populations
- 52 (44.3% at AC, 26.5% in hospital).

53 CONCLUSIONS

- 54 Sensitivity of ID NOW SARS-CoV-2, compared to RT-PCR, is very high during the BA.1
- 55 Omicron wave, and is significantly higher when compared to previous SARS-CoV-2 variant
- 56 waves.
- 57

58 Keywords: ID NOW, COVID-19, SARS-CoV-2, POCT, rapid diagnostics, symptomatic

- 59
- 60
- 61
- 62
- 63
- 64
- 65
- 66

67 **INTRODUCTION**

68 The ID NOW (Abbott, Illinois, United States) is approved by the United States Food and Drug 69 Administration (FDA) Emergency Use Authorization for the point of care, rapid detection of 70 severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2) in individuals who are within the first 7 days of symptom onset.¹ The ID NOW assay uses isothermal nucleic acid 71 72 amplification of a region of the viral RNA-dependent RNA polymerase (RdRp) to detect the 73 presence of SARS-CoV-2, with results available in under 15 minutes. Clinical specimens 74 approved by U.S. FDA for testing include nasal, oropharyngeal (OP), and nasopharyngeal swabs 75 (NP), which must be tested on the Abbott ID NOW either immediately or within one hour of 76 collection. Specimens placed in viral/universal transport media (UTM) are not valid for testing by the Abbott ID NOW.¹ 77

78

79 Since December 4, 2020 the ID NOW has been used in various settings throughout Alberta, 80 Canada (4.4 million people). This includes 42 COVID-19 assessment centres and 69 rural 81 hospitals. We previously prospectively evaluated the ID NOW performance among symptomatic 82 individuals in these sites prior to the Omicron variant wave. The clinical sensitivity and 83 specificity of the ID NOW among symptomatic individuals presenting to assessment centres 84 (community swab centres) was 92.5% [95% confidence interval (CI) 92.0-93.0%] and 99.5% 85 (95% CI 99.4-99.5%), respectively (n=70.879 with 10,633 RT-PCR positive). The clinical 86 sensitivity and specificity of the ID NOW among symptomatic individuals in hospital was 89.5% 87 (95% CI 88.3-90.6%) and 99.3% (95% CI 99.2-99.4%), respectively (n=16,924 with 2,932 RT-PCR positive).² 88

90	Currently, there is a paucity of data on the ID NOW performance in the setting of the Omicron
91	variant. Abbott has reported that mutations found in the Omicron variant does not affect the
92	performance based on <i>in silico</i> data. ³ Due to the different growth kinetics, transmissibility and
93	tissue tropisms than other variants and emergence in a population with 72% vaccination ⁴ , the
94	performance with Omicron may be different and clinical validation is justified. ⁵
95	
96	Our aim was to assess ID NOW's clinical performance among symptomatic individuals
97	presenting to assessment centres and patients in emergency rooms and hospitals during a time
98	when the Omicron variant represented the majority of SARS-CoV-2 detected within our
99	population.
100	
101	METHODS
102	Since December 4, 2020, the ID NOW was gradually implemented across Alberta in the
103	following sites:
104	1) 42 COVID-19 Alberta Health Services (AHS) Public Health assessment/swabbing centres,
105	located in all regions of Alberta: testing of symptomatic individuals and asymptomatic close
106	contacts. These are the primary locations for community patients not needing medical attention
107	to get tested for COVID-19 in Alberta. Testing and swabbing was performed by assessment
108	centre staff (e.g. nurses) within Alberta Precision Laboratories (APL) approved Point of Care
109	Testing (POCT) programs.
110	2) 69 rural hospitals located across Alberta: testing of symptomatic inpatients or ED patients.
111	Swabbing was performed by physicians, nurses, or respiratory therapists. Testing was performed
112	in a College of Physician and Surgeons of Alberta (CPSA) accredited hospital laboratory (APL).

The collection and testing of COVID-19 samples followed the same procedures as described in
our previous paper.² We chose to analyze data from January 5 – 18, 2022, when Omicron
represented >95% of SARS-CoV-2 variants detected in our population. Not all individuals with
ID NOW positive samples had samples collected for testing of variants of concern, due to
changes in our testing protocols designed to conserved lab capacity.

120 Individuals were given the option to have POCT by ID NOW and routine testing, or routine 121 testing alone. All individuals tested with the ID NOW had two parallel swabs collected. The first 122 swab collected was either a NP swab or OP swab, which was placed in UTM (Yocon Biology, 123 Beijing, China or GDL Korea Co. Ltd, Seoul, Korea) for RT-PCR, and transported to an 124 accredited laboratory at room temperature and stored at 4°C until processing. The second swab 125 was an OP swab for ID NOW testing (using the OP swab provided in the ID NOW kits). The OP 126 swab for ID NOW testing was always collected second to ensure all individuals had a sample 127 available for RT-PCR (i.e. in case the individual refused the second NP or OP swab). If the ID 128 NOW test was negative, the second swab was sent for confirmatory RT-PCR testing. If the ID 129 NOW test was positive, the second swab was either sent for storage or for variant of concern 130 screening (VoC) testing. All RT-PCR tests sent for variant testing were done within 131 approximately 72 hours from time of collection. During the Omicron wave, only a subset of 132 positive samples were sent for variant testing due to resourcing pressures faced by our 133 laboratory. Positive ID NOW results without subsequent variant testing were considered true 134 positives in this study.

136	All RI-PCR testing was performed on the APL Public Health Laboratory E gene PCR or on a
137	Health Canada and FDA approved commercial assay. ⁶ Commercial assays were dependent on
138	the testing lab and included the Allplex (Seegene, Seoul, South Korea), BDMax (Becton
139	Dickinson, NJ, United States), Panther (Hologic, MA, United States), GeneXpert SARS-CoV-2
140	or SARS-CoV-2/Influenza/RSV (Cepheid, CA, United States), Cobas 6800 System (Roche
141	Molecular Systems, CA, United States) and Simplexa (DiaSorin, Saluggia, Italy). All samples
142	sent for VoC screening were tested with the ProvLab E gene assay to determine if sufficient viral
143	load was present for VoC testing. E gene RT-PCR results from our lab-developed test were
144	considered positive for SARS-CoV-2 when E gene cycle threshold (Ct) value was <35.
145	If the Ct was \geq 35, amplification from the same eluate was repeated in duplicate and was
146	considered positive if at least $2/3$ results had a Ct <41 .

ADI D 11' II

1.1 7 1

DOD

147

100

c

1

.1

148 All personnel performing the ID NOW swabbing/testing were trained healthcare workers 149 (HCW), who were previously trained in NP and oropharyngeal swab collection. At time of 150 collection, they asked and recorded whether the patient had symptoms or was asymptomatic. All 151 sites and HCW were trained on the ID NOW collection, transport, and testing processes, at least 152 according to the manufacturer's instructions, prior to ID NOW implementation. AHS staff were 153 trained according to the APL POCT program, which meets CPSA accreditation standards. Each 154 ID NOW device underwent a verification process, which included testing 3 positive ID NOW 155 control swabs and 5 negative ID NOW control swabs on the ID NOW instrument before use. 156 One positive control and one negative control swab were tested on the ID NOW instrument after 157 each new box of ID NOW kits was opened, after each new HCW was trained on the instrument, 158 and, after each instrument was transported to a different site.

159	Samples were included for all ID NOW results collected at assessment centres or hospitals
160	among symptomatic individuals. Results without proper documentation of testing location, or
161	without confirmatory RT-PCR, if ID NOW negative, were excluded.
162	
163	Data was pulled from our provincial laboratory's centralized electronic database containing
164	SARS-CoV-2 results for all publicly funded testing in the province except for border testing.
165	Sensitivity and specificity of the ID NOW was calculated with Clopper-Pearson 95% confidence
166	intervals. Statistical analysis was performed using Pearson Chi-squared for categorical variables
167	and t-test for continuous variables using STATA (version 14.1).
168	
169	The University of Alberta Research Ethics board approved this study (Pro00111835).
170	
171	RESULTS
172	A total of 3,498 results were identified between January 5-18, 2022. 457 samples were excluded:
173	35 did not have testing location recorded, 24 did not have an ID NOW result recorded and 398
174	ID NOW negative results did not have parallel RT-PCR results recorded. The remaining 3,041
175	paired samples were analyzed.
176	
177	Of the 3,041 paired samples, 1,873 were collected from 42 assessment centres and 1,168 from 69
178	rural hospitals. Baseline characteristics and variant test results of these samples are provided in
179	Table 1. Results, compared to RT-PCR, are provided in Table 2 and Figure 1. In both assessment
180	centres and hospitals, ID NOW positivity rate was extremely high at 44.3% and 26.5%,
181	respectively, and is consistent with SARS-CoV-2 positivity rates observed among other COVID-

182	19 diagnostic platforms during the same time [AHS Surveillance Data]. ID NOW sensitivity was
183	higher among symptomatic individuals presenting to assessment centres (96.0%, 95% CI 94.5-
184	97.3%, n=830 RT-PCR positive) compared to symptomatic patients in hospital (91.6% (95% CI
185	87.9-94.4%, n=309 RT-PCR positive). ID NOW specificity, negative predictive value (NPV),
186	and positive predictive value (PPV) among symptomatic individuals presenting to assessment
187	centres was 97.8% (95% CI 96.7-98.6%), 96.9% (95% CI 95.7-97.7%), and 97.2% (95.9-98.1%),
188	respectively. ID NOW specificity, NPV, and PPV among symptomatic individuals in hospital
189	was 98.6% (95% CI 97.6-99.3%), 97.0% (95.8-97.9%), and 95.9% (93.1-97.6%), respectively.
190	
191	E gene Ct values for ID NOW true positive and true negative results are provided in Table 1.
192	Mean E gene Ct values were higher among ID NOW false negatives compared to true positives,
193	but were only statistically significant for hospital patients (p<0.001).

195 DISCUSSION

196 Use of point of care SARS-CoV-2 tests, such as the ID NOW, for the detection of SARS-CoV-2 197 among individuals remains a worthwhile endeavour. At time of writing, this is the first study to 198 evaluate the ID NOW during the Omicron variant wave. In the face of Omicron, our study demonstrated increased ID NOW sensitivity compared to prior variant waves.² The ID NOW 199 200 sensitivity in assessment centres before Omicron (as of November 24, 2021) was 92.5% (95% CI 201 92.0-93.0%). Our current data during the Omicron wave has demonstrated a higher ID NOW 202 sensitivity of 96.0% (95% CI 94.5-97.3%). Sensitivity in hospital settings also increased with the 203 Omicron wave, though the difference was not statistically significant (pre-Omicron it was 204 89.5%, 95% CI 88.3-90.6%, compared to 91.6% during Omicron, 95% CI 87.9-94.4%). In

respose to this study and the high sensitivity in previous waves, our provincial laboratory no
longer requires confirmation of negative ID NOW results when tested on symptomatic
individuals presenting to community assessment centres within 7 days of symptom onset.

208

209 In the current Omicron study and our previous ID NOW study sensitivity was slightly lower in 210 hospital settings compared to community assessment centres. However, its performance was still 211 higher for Omicron than what we previously observed, but not statistically significant (likely due to the lower sample size in our Omicron study).² There may be various factors to account for the 212 213 decreased ID NOW sensitivity observed among hospitals compared to assessment centres. 214 Firstly, ID NOW testing is performed immediately after sample collection at assessment centres, 215 whereas hospitals require transportation to the on-site lab prior to ID NOW testing. While ID 216 NOW testing was mandated to be done within 1 hour from collection, short periods of time from transportation may potentially affect performance.⁷ Secondly, a higher proportion of individuals 217 218 with lower viral loads may be tested in emergency rooms, as a result of patients commonly 219 presenting to hospital later in their symptom onset course, which is associated with higher SARS-CoV-2 E gene Ct values.^{8,9} Symptomatic individuals presenting to assessment centres, in 220 221 comparison, are often within the first few days of symptom onset, but because it generally takes 222 approximately 24 hours to arrange a booking, are not at the very beginning of their symptom 223 onset.

224

Why ID NOW sensitivity improved in the face of Omicron is not fully known. There have been reports that the SARS-CoV-2 viral loads observed among clinical specimens with the Omicron variant are not different from clinical specimens of other variants.^{10,11} There are suggestions that

Omicron has altered tissue tropism compared to prior variants which may make sampling from the oropharynx more reliable.¹² Higher COVID-19 prevalence during the Omicron wave could have also contributed. Positivity rate for all COVID-19 tests done during the study period in Alberta was 36.74% compared to 4.27% and 9.09% during the wild type peaks (April 2020 and December 2020), 13.56 for alpha (May 2021), and 13.47% for Delta (September 2021) [AHS surveillance dashboard].

234

235 Interestingly, a high proportion (87.0%) of the false positives detected in our study, among 236 individuals at assessment centres, were from samples collected using a nasopharyngeal swab. 237 Due to the many (45.5%) ID NOW positive samples that were subsequently not tested for 238 variants in our study, the specificity calculated in our study is likely even lower. The reasons 239 behind reduced specificity is unclear, but potentially related to altered tissue tropism favouring 240 samples from the oropharynx over the nasopharynx when tested earlier in the COVID-19 241 infection course.13 Lower specificity is unlikely to be explained by other factors, such as SARS-242 CoV-2 contamination, given that our testing was conducted across over 100 sites and there has 243 not been prior reports of contamination or high rates of false positive results with the ID NOW in 244 the literature.

245

Strengths of this study include the large sample size studied in various real-world locations,
including community COVID-19 assessment centres and hospitals. Due to the same testing sites,
procedures, and methodology, the results during Omicron can be accurately compared to our
results from before Omicron.² Due to the routine surveillance testing of many positive ID NOW
or RT-PCR samples for variants of concern, which included E gene RT-PCR from a consistent

RT-PCR testing platform (APL LDT), we were able to roughly assess the specificity of the ID
NOW and examine the relationship of E gene Ct values between true positive and false negative
ID NOW results in the face of Omicron.

254

255 Our study had several limitations. Due to the heterogeneity of our populations tested, it is 256 difficult to exclude confounders that may have contributed to ID NOW performance. However, 257 we previously observed no differences in sensitivity based on common patient, collecting and testing characteristics, including age, gender, and swab type.² Our current study also did not 258 259 demonstrate any difference in performance with these characteristics, though the sample size was 260 not large enough to make any concrete conclusions. Another limitation is the inability to 261 exclusively study Omicron by itself. While the Delta variant only represented 0.7% of variants 262 detected from the assessment centres during our study period, there was still a moderately high 263 proportion (14.5%) of delta variant still circulating within our hospitals. This study did not assess 264 the Omicron BA.2 sublineage, as it was not circulating in our population during the study period. 265

Other limitations include missing parallel RT-PCR results that could affect the sensitivity
observed in our study. As previously mentioned, many (45.5%) ID NOW positive samples did
not undergo variant testing which would affect our calculated specificity. ID NOW sensitivity
may be slightly lower than we calculated due to the exclusion of 398 ID NOW negative samples
that subsequently did not have a second sample tested with RT-PCR. Reasons behind missing
parallel RT-PCR are multifactorial and include sample lost or discarded prior to testing, testing
sites going against guidelines and not obtaining a second swab for RT-PCR confirmation, and

273	patient demographic mismatches resulting in test cancellation or inability to match ID NOW and
274	RT-PCR tests together in our electronic database.

- 276 In conclusion, the performance of the ID NOW improved in sensitivity during the Omicron BA.1
- 277 wave. Reasons for improved sensitivity may potentially be related to increased COVID-19
- 278 prevalence and/or altered tissue tropism favouring the oropharynx early in the COVID-19

279 infection course. More research is required to prove this claim.

280

281 Acknowledgments

282 This work was funded using internal operating funds of Alberta Precision Laboratories and

283 Alberta Health Services (AHS). Test kits and instruments were paid for by the Public Health

284 Agency of Canada. We thank staff at AHS assessment centre and contracted mobile teams for

collecting and testing samples in the community, and Alberta Precision Laboratory staff for

assistance with testing of samples, and in the development and support of the various testing

programs.

288

289 **Declarations**

290 Funding: Internal funding from Alberta Precision Laboratories and Alberta Health Services.

291 *Conflict of Interest:* The manufacturer had no role to play in the study. The authors have no

- 292 conflict of interests to disclose pertaining to this study.
- 293 Availability of data: Available upon request.

294

295

296

298 **REFERENCES**

- United States Food and Drug Administration. ID NOW COVID-19 instructions for use.
 2020. [Accessed Feb 10, 2022]. Available from: https://www.fda.gov/media/136525/download
- Stokes W, Venner AA, Buss E, Tipples G, Berenger BM. Then and NOW: a prospective population-level validation of the Abbott ID NOW SARS-CoV-2 device implemented in multiple settings for testing asymptomatic and symptomatic individuals. MedRxiv 2022.04.30.22274189; doi:https://doi.org/10.1101/2022.04.30.22274189
- 306
 3. Abbott. Evaluating Omicron and other COVID variants to ensure test effectiveness.
 307 [Accessed Feb 27, 2022]. Available from: 308 https://www.abbott.com/corpnewsroom/diagnostics-testing/monitoring-covid-variants-to-309 ensure-test-effectiveness.html
- 310
 311
 4. Government of Alberta. 2022. [Accessed Feb 27, 2022]. Available from: https://www.alberta.ca/stats/covid-19-alberta-statistics.htm
- 5. Zhao H, Lu L, Peng Z, et al. SARS-CoV-2 Omicron variant shows less efficient
 replication and fusion activity when compared with Delta variant in TMPRSS2-expressed *Emerg Microbes Infect.* 2022;11(1):277-283.
 - 6. Pabbaraju, et al. Development and validation of reverse transcriptase-PCR assays for the testing of SARS-CoV-2. *JAMMI*. 2020. Doi:10.3138/jammi-2020-0026: e20200026
 - Stokes W, Berenger BM, Singh T, et al. Acceptable performance of the Abbott ID NOW among symptomatic individuals with confirmed COVID-19. *J Med Microbiol*. 2021;70(7):001372. PMID: 34309503.
 - 8. Stokes W, Kanji JN, Hu J, Zelyas N, Berenger BM. Wide variation in threshold cycle values clouds the interpretation of SARS-CoV-2 infectiousness. *Clin Chem.* 2021;68(1):253-255.
 - 9. Peacock WF, Soto-Ruiz KM, House SL, et al. Utility of COVID-19 antigen testing in the emergency department. *J Am Coll Emerg Physicians Open*. 2022 Jan 15;3(1):e12605.
 - 10. Hay JA, Kissler SM, Fauver JR, et al. Viral dynamics and duration of PCR positivity of the SARS-CoV-2 Omicron variant.
 - medRxiv 2022.01.13.22269257; doi:https://doi.org/10.1101/2022.01.13.22269257
 - 11. Puhach O, Adea K, Hulo N, et al. Infectious viral load in unvaccinated and vaccinated patients infected with SARS-CoV-2 WT, Delta and Omicron. medRxiv 2022.01.10.22269010; doi:https://doi.org/10.1101/2022.01.10.22269010
 - 12. Marais G, Hsiao N, Iranzadeh A, et al. Saliva swabs are the preferred sample for Omicron detection.
 - medRxiv 2021.12.22.21268246; doi:https://doi.org/10.1101/2021.12.22.21268246
- Adamson B, Sikka R, Wyllie AL, Premsrirut P. Discordant SARS-CoV-2 PCR and rapid
 antigen test results when infectious: A December 2021 occupational case series. medRxiv
 2022.01.04.22268770. https://doi.org/10.1101/2022.01.04.22268770
- 337

315

316

317

318

319

320

321

322

323

324

325

326 327

328

329 330

331

332

333

- 338 339
- 339 340
- 341
- 341 342
- 342 343

Table 1: Characteristics between individuals tested with ID NOW SARS-CoV-2

Site	Assessment centre	Hospital
Mean age (median, range)	38.6 (38.0, 0.5-85.8)	51.3 (55.2, 0.09-
		103.2)
Male gender	33.1%	48.8%
NP swab used for parallel RT-PCR	78.3%	92.1%
testing [*] (%)		
Variant ^{**} (%)	Omicron (89.3%)	Omicron (70.4%)
	Delta (0.7%)	Delta (14.5%)
	Unresolved (10.0%)	Unresolved (15.0%)
Mean E gene Ct value from variant	22.7 (21.6, 14.5-40.9)	22.6 (21.5,15.2-38.1)
testing of true positives (median,		
range)		
Mean E gene Ct value from variant	25.8 (25.4, 21.6-34.5)	32.1 (34.1, 17.1-36.7)
testing of false negatives (median,		
range)		

364 365 366 367 NP: nasopharyngeal Ct: Cycle threshold

*Either NP or oropharyngeal swab was used for parallel RT-PCR testing. In hospitalized patients, a minority of samples were other specimen types such as endotracheal tube aspirates. **n=428 for assessment centres, n=193 for hospital

Assessment Centre				
		RT-PCR		
		Positive	Negative	
ID NOW	Positive	797	23	
	Negative	33	1020	
Hospital				
	RT-PCR			
		Positive	Negative	
ID NOW	Positive	283	12	
	Negative	26	847	

Table 2: Performance of ID NOW, compared to RT-PCR, using oropharyngeal swabs.

Figure 1: Sensitivity and specificity of ID NOW (oropharyngeal swab) compared to RT-PCR

(oropharyngeal swab or nasopharyngeal swab). Error bars represent 95% confidence intervals. AC = assessment centre.

